Exosomes: From “Dust” to Multiplexed Diagnostic BiomarkerMonday, 23 March 2015 at 09:00 Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com Exosomes are nano-sized vesicles released by all cell types and their protein and RNA cargo mirror the composition of their originating cells. In the case of cancer cells, the released exosomes exhibit proteins and RNA associated with the tumor and can be used as surrogates to define tumor type and stage and to predict therapeutic responses. While exosomes possess the FDA-defined features of ideal biomarkers and can be easily obtained and assessed, several obstacles have limited their clinical applications. The most critical barrier to their diagnostic application is the isolation of disease-specific exosomes and characterization their cargo. Emerging technologies will be discussed by the isolation of exosomes, associated specifically with cancers, allowing their use in diagnosis, patient stratification for therapy, monitoring therapeutic responses in real time and early identification of recurrence. These approaches target the unique properties and compositions of specific vesicle populations. The isolation of enriched pathology-specific vesicles enhances the signal to noise ratio and allows the identification of markers directly derived from the specific cell types. By correlating these circulating markers with the molecular characteristics and real-time clinical parameters, the use of circulating vesicles represents the ideal, multiplexed marker platform for clinical management. Exosomes: From “Dust” to Multiplexed Diagnostic BiomarkerMonday, 23 March 2015 at 09:00 Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com Exosomes are nano-sized vesicles released by all cell types and their protein and RNA cargo mirror the composition of their originating cells. In the case of cancer cells, the released exosomes exhibit proteins and RNA associated with the tumor and can be used as surrogates to define tumor type and stage and to predict therapeutic responses. While exosomes possess the FDA-defined features of ideal biomarkers and can be easily obtained and assessed, several obstacles have limited their clinical applications. The most critical barrier to their diagnostic application is the isolation of disease-specific exosomes and characterization their cargo. Emerging technologies will be discussed by the isolation of exosomes, associated specifically with cancers, allowing their use in diagnosis, patient stratification for therapy, monitoring therapeutic responses in real time and early identification of recurrence. These approaches target the unique properties and compositions of specific vesicle populations. The isolation of enriched pathology-specific vesicles enhances the signal to noise ratio and allows the identification of markers directly derived from the specific cell types. By correlating these circulating markers with the molecular characteristics and real-time clinical parameters, the use of circulating vesicles represents the ideal, multiplexed marker platform for clinical management. Exosomes: From “Dust” to Multiplexed Diagnostic BiomarkerMonday, 23 March 2015 at 09:00 Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com Exosomes are nano-sized vesicles released by all cell types and their protein and RNA cargo mirror the composition of their originating cells. In the case of cancer cells, the released exosomes exhibit proteins and RNA associated with the tumor and can be used as surrogates to define tumor type and stage and to predict therapeutic responses. While exosomes possess the FDA-defined features of ideal biomarkers and can be easily obtained and assessed, several obstacles have limited their clinical applications. The most critical barrier to their diagnostic application is the isolation of disease-specific exosomes and characterization their cargo. Emerging technologies will be discussed by the isolation of exosomes, associated specifically with cancers, allowing their use in diagnosis, patient stratification for therapy, monitoring therapeutic responses in real time and early identification of recurrence. These approaches target the unique properties and compositions of specific vesicle populations. The isolation of enriched pathology-specific vesicles enhances the signal to noise ratio and allows the identification of markers directly derived from the specific cell types. By correlating these circulating markers with the molecular characteristics and real-time clinical parameters, the use of circulating vesicles represents the ideal, multiplexed marker platform for clinical management. |